Welcome to Cosmo Pharmaceuticals

Cosmo is an emerging fully-integrated speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn’s Disease, as well as for colon infections.

Therapeutic Focus

Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders leading to the damage of the gastro-intestinal tract. The main forms of IBD are Ulcerative Colitis and Crohn’s Disease. Both diseases are clinically similar and may be described as a faulty regulation of the mucosal immune response.

Business Fields

Cosmo is engaged in two distinct fields:

• Development and commercialisation of proprietary drugs, primarily focused on the treatment of Inflammatory Bowel Diseases and colon infections.
• Manufacturing of pharmaceutical products for third parties and the provision of related services.

Price	15.60
Date	03/07/2009
Time	14:53 CEST
Change	-0.40
Market cap	CHF 216.4 mln
Data is delayed by approximately 20 minutes